Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 20, 2005. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to reporting specific share transactions and does not contain financial performance data.
Material Changes
The primary material change reported is a transaction involving the GlaxoSmithKline Employee Trust ("the GSK Trust"). On April 19, 2005, Abacus (GSK) Trustees Limited transferred 5,022 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. The company was advised of this transaction on April 20, 2005.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It strictly details the mechanics of the share transfer and the nature of the GSK Trust as a discretionary trust for current and former employees.
Investor Verification Points
- Verify the impact of the 5,022 share transfer on the total outstanding share count.
- Confirm the specific directors (Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop) who hold interests in the GSK Trust.
- Review the terms of the SmithKline Beecham Employee Share Option Plan 1991 to understand the vesting or exercise conditions for the recipients.